C(C1C=C2C(=CC=1)NC(=O)/C/2=C\C1NC=CC=1)#C.[CH3:19][O:20][C:21]1[CH:25]=[CH:24][NH:23][C:22]=1/[CH:26]=[C:27]1\[C:28](=[O:42])[NH:29][C:30]2[C:35]\1=[CH:34][C:33]([C:36]#[C:37][Si](C)(C)C)=[CH:32][CH:31]=2.[C-]#N.[K+]>C(O)C.O1CCCC1.O.[N+]([O-])([O-])=O.[Ag+]>[C:36]([C:33]1[CH:34]=[C:35]2[C:30](=[CH:31][CH:32]=1)[NH:29][C:28](=[O:42])/[C:27]/2=[CH:26]\[C:22]1[NH:23][CH:24]=[CH:25][C:21]=1[O:20][CH3:19])#[CH:37]
This compound was also prepared in a manner analogous to the preparation of (Z)-1,3-dihydro-5-ethynyl-3-[(1H-pyrrol-2-yl)methylene]-2H-indol-2-one in Example 82 above. In this example, (Z)-1,3-dihydro-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-5-(trimethylsilyl)ethynyl-2H-indol-2-one (100 mg, 0.3 mmol) (Example 92) in 5 mL ethanol and 1.5 mL tetrahydrofuran was treated with silver nitrate (0.112 g, 0.6 mmol) in 1.5 mL ethanol and 0.5 mL water, followed by potassium cyanide (218 mg, 3.35 mmol) in 1 mL water to give 70 mg (89%) of (Z)-1,3-dihydro-5-ethynyl-3-[(3-methoxy-1H-pyrrol-2-yl)methylene]-2H-indol-2-one (61 mg after recrystallization).
読み込み中…
